Amgen to Negotiate Enbrel Prices Under IRA, Targeting $1.5B Medicare Savings
AMGN sits 39% above its 52-week low of $261.43.
Summary
Amgen's Immunex subsidiary will enter negotiations for Enbrel prices under the Inflation Reduction Act, a move expected to save Medicare enrollees approximately $1.5 billion in 2026. This development signals a direct financial impact from the IRA's drug pricing provisions, potentially reducing revenue for Amgen from one of its key products. Separately, the company's Board of Directors declared a routine quarterly dividend of $2.52 per share for Q2 2026, payable on June 5, 2026. While the dividend is a standard capital allocation, the Enbrel price negotiation represents a material regulatory headwind that traders will monitor for its effect on future earnings.
At the time of this announcement, AMGN was trading at $363.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.9B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.